Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2015 Mar 2;125(3):1365. doi: 10.1172/JCI81182

Complement as a multifaceted modulator of kidney transplant injury

Paolo Cravedi, Peter S Heeger
PMCID: PMC4362224  PMID: 25729858

Original citation: J Clin Invest. 2014;124(6):2348–2354. doi:10.1172/JCI72273.

Citation for this corrigendum: J Clin Invest. 2015;125(3):1365. doi:10.1172/JCI81182.

In the original article, it was incorrectly stated that “Human CD46 (murine homolog Crry), also known as membrane cofactor protein (MCP), has similar decay-accelerating function, but also exhibits cofactor activity.” Human CD46 has only cofactor activity; it does not have decay-accelerating activity. The corrected sentences appear below.

Page 2348:

Human CD46, also known as membrane cofactor protein (MCP), exhibits cofactor activity: in conjunction with soluble factor I, this membrane-bound regulator inactivates C3b to iC3b, thereby preventing reformation of the C3 convertase. The murine homolog of CD46, Crry, has both cofactor activity and decay-accelerating activity.

The authors regret the error.

Footnotes

See the related article beginning on page 2348.


Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES